Daily FNArena News - Australia

ResMed has struggled to realise the benefit promised by a major competitor recall and heightened demand amid a global shortage of semiconductor chips necessary for device production

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

Following first half results for Premier Investments, brokers generally set higher target prices and noted leverage towards both stay-at-home and re-opening thematics

With a potential end in sight for Fisher & Paykel Healthcare’s covid benefits the company looks to prove its ventilation devices have a place outside of intensive care units and rebuild utilisation rates for a sustainable outlook

Following first half results for New Hope, brokers focused not only on the surprise special dividend but also on prospects for future distributions

FNArena’s Monitor keeps track of corporate earnings result releases, including broker views, ratings and target price changes and beat/miss assessments

The current share price might be underestimating potential upside for Seek

Two of Rio Tinto’s major growth projects are currently beholden to geopolitical influences, positive and negative, and it’s got nothing to do with the war

New broker research suggests the time may be right to buy shares in Tyro Payments, after a general decline in technology shares and a negative market reaction to recent first half results

Investment in increased operations capacity is supporting a return to growth for Costa Group, with the company to benefit from expanded production coupled with a strong pricing environment